Clinical trials
Observational Postoperative Complications trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Recruiting | 4 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Radboud University Medical Center | 2 |
| UMC Utrecht | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Amsterdam UMC, location VUmc | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Christian S. Meyhoff | 1 |
| Instituto de Investigacion Sanitaria La Fe | 1 |
| Leiden University Medical Center | 1 |
| Maastricht University Medical Center | 1 |
| Mark Coburn | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Postoperative Complications | 16 |
| Intraoperative Complications | 2 |
| Myocardial Infarction | 2 |
| Acute Coronary Syndrome | 1 |
| Acute Pain | 1 |
| Basal Cell Carcinoma | 1 |
| Colonic Neoplasms | 1 |
| Coronary Artery Disease | 1 |
| Cutaneous Squamous Cell Carcinoma | 1 |
| Death | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.